Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Bluejay Diagnostics ( (BJDX) ) is now available.
On November 10, 2025, Bluejay Diagnostics announced its third-quarter financial results and corporate updates, highlighting advancements in clinical milestones and strategic partnerships. The company reported progress in the SYMON-II clinical trial, aiming for FDA clearance and product commercialization, and completed a private placement transaction in October 2025. Bluejay is focused on sepsis diagnostics, with plans to submit a 510(k) application to the FDA in 2027, contingent on securing further financing.
Spark’s Take on BJDX Stock
According to Spark, TipRanks’ AI Analyst, BJDX is a Underperform.
Bluejay Diagnostics’ stock is heavily impacted by its poor financial performance, with no revenue and continuous losses. The technical indicators suggest a bearish trend, and valuation is challenging due to the negative P/E ratio. Improvements in equity are noted but overshadowed by the lack of profitability and revenue generation.
To see Spark’s full report on BJDX stock, click here.
More about Bluejay Diagnostics
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes through its Symphony System, a rapid, near-patient testing system for sepsis triage and monitoring. The company aims to provide accurate results in approximately 20 minutes to aid medical professionals in making better treatment decisions. Bluejay is working towards obtaining regulatory clearance from the U.S. FDA for its Symphony System.
Average Trading Volume: 4,115,858
Technical Sentiment Signal: Sell
Current Market Cap: $2.85M
See more data about BJDX stock on TipRanks’ Stock Analysis page.